News
-
According to Pearl Therapeutics, a randomized, double-blind, dose-ranging Phase 2b study of its PT003 formoterol fumarate (FF)/glycopyrrolate (GP) MDI for the treatment of moderate-to-severe COPD in more than a thousand patients showed that several doses… Read more . . .
-
Raleigh, NC, inhalation company. This position involves managing the R&D MDI processing laboratory at our client’s Raleigh, NC site. The primary functions will be to lead the development and scale-up of the MDI filling process,… Read more . . .
-
Raleigh, NC, inhalation company. The Analytical Director will have responsibility for the strategic oversight of analytical operations including method development, validation and implementation, as well as analytical method transfers, and the support of regulatory submissions… Read more . . .
-
A number of companies that provide products and services for inhaled and nasal drugs had booths at the 2012 AAPS annual meeting. Click on thumbnails for larger versions. Read more . . .
-
The 2012 annual meeting of the American Association of Pharmaceutical Scientists, which took place from October 14-18 at the McCormick Place convention center in Chicago, drew a number of inhalation and nasal specialists for the… Read more . . .
-
On October 17, MannKind Corporation announced a plan to sell 40,000,000 shares of its common stock, plus warrants to purchase up to 30,000,000 shares, in a public offering, which it said may or may not… Read more . . .
-
Market research firm Frost & Sullivan is presenting its 2012 Global Enabling Technology Award to Alexza Pharmaceuticals for its Staccato thermal vaporization inhaler platform. The award is designed to recognize a company for “developing a… Read more . . .
-
Contract manufacturer PharmaForm, a subsidiary of Akela Pharma, has announced plans to move from Austin, TX to the San Diego, CA area. The company offers formulation and manufacturing services for numerous dosage forms, including nasal… Read more . . .
-
MAP Pharmaceuticals has resubmitted its New Drug Application (NDA) for Levadex inhaled dihydroergotamine for the treatment of migraine to the FDA, the company has announced. The FDA issued a complete response letter to MAP in… Read more . . .
-
According to Chiesi Group, a Phase 1 trial of its inhaled phosphodiesterase 4 (PDE4) inhibitor for the treatment of lung diseases such as COPD and asthma demonstrated that the drug, known as CHF 6001, was… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland